WuXi XDC sets its Hong Kong IPO price at high end of range

A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong. The company said Wuxi XDC Cayman will raise 3.68 billion Hong Kong dollars, the equivalent of $470.9…#wuxibiologics #hongkong #wuxixdccayman #wuxi #invesco #qatar #hongshan #sequoiacapitalchina #wuxixdcs
Source: Reuters: Health - Category: Consumer Health News Source Type: news